ERBB2 and breast cancer: It has been suggested that MAP3K1 might act as an essential factor for promoting cell proliferation, migration, invasion, and drug resistance, increasing local recurrences and metastases of hormone receptor (HR)-positive/HER2-negative early-stage BC [34].